First randomized trial of a radiopharmaceutical in kidney cancer finds no skeletal benefit
Results of the Alliance for Clinical Trials in Oncology's Phase II RadiCaL trial (Alliance A031801), the first randomized study of a radiopharmaceutical in kidney cancer, found that adding radium-223 to standard care did not improve the length of time patients went without serious bone complications (called skeletal event-free survival) in patients with advanced kidney cancer.
A Phase II randomized trial, the first of its kind in kidney cancer, has concluded that adding radium-223 to standard care did not provide any additional benefit in delaying serious bone complications, known as skeletal events, in patients with advanced kidney cancer. The study, conducted by the Alliance for Clinical Trials in Oncology (Alliance A031801) and published in the Journal of Clinical Oncology, enrolled 98 patients at 29 cancer centers across the United States.
Radium-223, a radioactive medication that mimics calcium and concentrates in bone, was combined with cabozantinib, a targeted oral cancer drug that inhibits tumor growth and blood supply. Despite the combination being well-tolerated, the study found no significant improvement in skeletal event-free survival compared to cabozantinib alone.
However, the researchers noted a numerically longer survival time with the combination, which is considered hypothesis-generating and requires further investigation.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
